Cancer Drug Access Unaffected By Medicare Sequester, CMS’ Blum Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Fears that sequestration cuts to Medicare Part B drug payments would lead to drug access issues have failed to materialize, CMS’ Jonathan Blum tells the FDA/CMS Summit.